CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.

Interactive atlas unveils immune changes in multiple myeloma

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health issues.

November 14, 2024

Opening Blood-Brain Barrier to Deliver Alzheimer’s Drug Shows Promise

Aducanumab (Aduhelm) infusions combined with focused ultrasound led to lower cerebral amyloid-beta levels in Alzheimer’s disease, a proof-of-concept trial showed. The investigational treatment involved creating

January 4, 2024

Edwards’ TAVR results hurt by pandemic aftereffects and competition in Q2

By the numbers Q2 Revenue: $1.53 billion 11% increase year-over-year Q2 Net income: $305.5 million 25% decrease year-over-year Q2 Earnings per share: $0.50 23% decrease

July 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.